Niacin: a long history, but a questionable future

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Biochemistry

Background:

• Niacin has been a long-standing treatment for dyslipidemia for nearly six decades.
• Understanding niacin's mechanisms of action is crucial for optimizing its therapeutic use.
• Recent research has shed light on niacin's effects on lipid profiles and its interaction with the GPR109A receptor.

Purpose of the Study:

• To review updated mechanistic data on niacin.
• To analyze recent clinical trial findings regarding niacin's efficacy.
• To provide insights into niacin's role in managing dyslipidemia and cardiovascular risk.

Main Methods:

• Review of recent mechanistic studies on niacin's action.
• Analysis of data from two major cardiovascular outcome trials (AIM-HIGH and HPS2-THRIVE).
• Examination of findings related to the niacin receptor GPR109A.

Main Results:

• Niacin-mediated fatty acid reduction and flushing depend on GPR109A receptor binding.
• Niacin's broader lipid-altering effects may occur independently of GPR109A interaction.
• Two large cardiovascular outcome trials failed to demonstrate a significant reduction in events.

Conclusions:

• Niacin remains an effective agent for lowering LDL cholesterol, particularly in patients with high LDL despite statin therapy.
• The failure of recent trials to show cardiovascular event reduction was unexpected.
• Further subgroup analyses are required to fully interpret the trial results and refine niacin's clinical application.